The FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Thrivent Financial for Lutherans lowered its position in shares of GSK plc (NYSE:GSK – Free Report) by 6.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 49,864 shares of the ...

GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating reaffirmed by equities research analysts at JPMorgan ...

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

GSK chief scientific officer Tony Wood stated ... in these trials was found to be consistent with earlier studies. Commercial launch in the US is planned for the second half of this year.

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

That involved working with GSK’s R&D, supply chain, and commercial units, to use data in a way that made sense for the company. Ramakrishnan says the company was an “early thinker” in ...

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.